Table 2 Patients’ characteristics at the time of first recurrence prior to CRT plus durvalumab (n = 24)

Median disease-free interval^a (months)

31.29

3–185

Frequency

%

Histological confirmation

13

54.2

Time to recurrence

Frequency

%

 < 1 year

10

41.7

 > 1 year

14

58.3

Pulmonary recurrence site

Frequency

%

 No pulmonary site

16

66.6

 At surgical staple lines

4

16.7

 Other lung sites

4

16.7

Lymph nodes relapse

Frequency

%

 Ipsilateral hilum

2

8.3

 Ipsilateral ilo-mediastinic

18

75.0

 Contralateral ilo-mediastinic

3

12.5

 Supraclavicular

1

4.2

PD-L1 expression

Frequency

%

 Negative

1

4.2

 ≤ 50%

11

45.9

 > 50%

12

50.0

PD-L1 assessment

Frequency

%

 At surgery

12

50.0

 At recurrence

12

50.0

ECOG performance status

Frequency

%

 0

15

62.5

 1

8

33.3

 2

1

4.2